2
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Unknown
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
10
Myeloid
7
Classical hematology
3
Lymphoid
2
Sarcoma
1
Plasma cell
1
Other solid neoplasm
1
Gynecologic
1
Gastrointestinal
1
Endocrine
1
Dermatologic
1
CNS
1
Breast
1
Conditions
Multiple Myeloma
3577
Neoplasms, Plasma Cell
696
Lymphoma
531
Lymphoma, Non-Hodgkin
480
Leukemia, Lymphocytic, Chronic, B-Cell
409
Hodgkin Disease
405
Recurrence
404
Precursor Cell Lymphoblastic Leukemia-Lymphoma
375
Leukemia
373
Leukemia, Myeloid, Acute
363
Myelodysplastic Syndromes
331
Lymphoma, Large B-Cell, Diffuse
290
Lymphoma, Mantle-Cell
288
Lymphoma, Follicular
284
Lymphoma, B-Cell, Marginal Zone
256
Burkitt Lymphoma
249
Immunoglobulin Light-chain Amyloidosis
227
Myeloproliferative Disorders
226
Lymphoma, Large-Cell, Immunoblastic
223
Neoplasms
214
Hematologic Neoplasms
200
Primary Myelofibrosis
186
Leukemia, Myeloid, Chronic-Phase
182
Leukemia, Myeloid, Accelerated Phase
173
Lymphoma, T-Cell, Cutaneous
170
Waldenstrom Macroglobulinemia
164
Blast Crisis
162
Leukemia, Myelomonocytic, Chronic
158
Mycosis Fungoides
147
Sezary Syndrome
146
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
GATA2 Deficiency
×
Plasma cell
×
Clear all
NCT03018405
2019-09-19
THINK
Celyad Oncology SA
Phase 1/2
Unknown
146 enrolled